Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL27705923 | 0.78 | LMNA (0.32) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8764955 | 0.77 | SMARCA2 (0.33) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL1199840 | 0.77 | LOXL2 (0.52) | — | |
| SCHEMBL29769017 | 0.77 | LOXL2 (0.52) | — | |
| SCHEMBL29738718 | 0.74 | LMNA (0.41) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL29508711 | 0.74 | UHRF1 (0.52) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL179285 | 0.74 | UHRF1 (0.52) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL278964 | 0.74 | LMNA (0.41) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL17194955 | 0.74 | LMNA (0.41) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL2259733 | 0.74 | LOXL2 (0.36) | SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2019-10-31 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8921555-B2 | Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones | MERCK SHARP & DOHME CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2011-05-26 | — | — | US | disclosed |
| WO-2009140163-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK & CO., INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | HIF1AN, HIF1A, EGLN2 | LMNA 4005/4885SMN1; SMN2 4257/4885NPC1 3927/4885 |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | LMNA 1954/4885SMN1; SMN2 588/4885NPC1 59/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | LMNA 710/4885SMN1; SMN2 923/4885NPC1 702/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | LMNA 635/4885SMN1; SMN2 1020/4885NPC1 249/4885 |
| US-20110124661-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | LMNA 4831/4885SMN1; SMN2 1055/4885NPC1 2542/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | LMNA 710/4885SMN1; SMN2 923/4885NPC1 702/4885 |
| US-11135207-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | LMNA 1954/4885SMN1; SMN2 588/4885NPC1 59/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | LMNA 3233/4885SMN1; SMN2 3406/4885NPC1 1692/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885SMN1; SMN2 837/4885NPC1 533/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | LMNA 1221/4885SMN1; SMN2 837/4885NPC1 533/4885 |
| US-20190328720-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CERS2, DEGS1, SMPD1 | LMNA 1954/4885SMN1; SMN2 588/4885NPC1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.